-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
-The study meets the two primary endpoints of ER+/HER2-advanced or metastatic breast cancer (mBC) patients
-Elacestrant is the first oral SERD to show positive top-line results in key clinical trials as a monotherapy in ER+HER2 advanced or mBC treatment compared with SoC
-Elacestrant prolongs the PFS of the total patient group and ESR1 mutation subgroup
-Plans to submit regulatory documents in the U.
-Plans to publish data at the San Antonio Breast Cancer Symposium in December 2021
Florence, Italy and Boston, October 22, 2021/PRNewswire/ - Menarini Group ("Menarini") and Radius Health, Inc.
This study aims to evaluate the efficacy and safety of Elacestrant as a single-agent therapy compared with standard care (SoC) in the treatment of patients with ER+/HER2- advanced or metastatic breast cancer
The EMERALD study reached two common primary endpoints: both the overall population and the ESR1 mutation subgroup had a statistically significant improvement in PFS
Menarini Group CEO Elcin Barker Ergun said: "We are very excited, because Elacestrant is the first in the treatment of ER+HER2 advanced or mBC, as a monotherapy, compared with SoC in key clinical trials.
Elacestrant is a selective estrogen receptor degrading agent (SERD)
Dr.
Radius Chief Executive Kelly Martin added: “Given the large number of COVID-19-related obstacles around the world, it takes a lot of effort to complete the EMERALD trial
The data is currently being fully evaluated
About the Phase 3 study of Elacestrant (RAD1901) and EMERALD
Elacestrant is a selective estrogen receptor degrading agent (SERD), which has been outsourced to Menarini Group and is currently being evaluated as a once-daily oral treatment for patients with ER+/HER2- advanced breast cancer
About Menarini
Menarini Group is a leading international pharmaceutical and diagnostic company with more than 17,000 employees and a turnover of 4.
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the fields of bone health, orphan diseases and oncology
Forward-looking statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995
These forward-looking statements are based on management's current expectations
Source: Menarini IFR
